Abstract

Only a subset of patients will typically respond to any given prescribed drug. The time it takes clinicians to declare a treatment ineffective leaves the patient in an impaired state and at unnecessary risk for adverse drug effects. Thus, diagnostic tests robustly predicting the most effective and safe medication for each patient prior to starting pharmacotherapy would have tremendous clinical value. In this article, we evaluated the use of genetic markers to estimate ancestry as a predictive component of such diagnostic tests. We first estimated each patient’s unique mosaic of ancestral backgrounds using genome-wide SNP data collected in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) (n = 765) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (n = 1892). Next, we performed multiple regression analyses to estimate the predictive power of these ancestral dimensions. For 136/89 treatment-outcome combinations tested in CATIE/STAR*D, results indicated 1.67/1.84 times higher median test statistics than expected under the null hypothesis assuming no predictive power (p<0.01, both samples). Thus, ancestry showed robust and pervasive correlations with drug efficacy and side effects in both CATIE and STAR*D. Comparison of the marginal predictive power of MDS ancestral dimensions and self-reported race indicated significant improvements to model fit with the inclusion of MDS dimensions, but mixed evidence for self-reported race. Knowledge of each patient’s unique mosaic of ancestral backgrounds provides a potent immediate starting point for developing algorithms identifying the most effective and safe medication for a wide variety of drug-treatment response combinations. As relatively few new psychiatric drugs are currently under development, such personalized medicine offers a promising approach toward optimizing pharmacotherapy for psychiatric conditions.

Highlights

  • It is well-known that only a subset of patients will respond to any given prescribed drug [1]

  • Predictive Power of Genotype-based Ancestry Figure 1 summarizes results of the regression analyses to test the null hypothesis that the five ancestral dimensions do not predict drug response using a Quantile-Quantile (QQ) plot for each of the drug-outcome combinations

  • The ordered, observed model fit F-test p-values are plotted against those expected under the null hypothesis of no true associations among the 136 (CATIE) or 89 (STAR*D) tests, represented by the straight line

Read more

Summary

Introduction

It is well-known that only a subset of patients will respond to any given prescribed drug [1]. Predicting drug nonresponse has, proven to be difficult. These challenges have led to a proliferation of pharmacogenetics research in the last decade. Genome-wide association studies (GWAS) systematically screening markers across the whole genome for association with drug response have been added as a tool to identify relevant genetic variants [5]. Before these genetic markers can be used in the clinic, they will need to be evaluated more extensively through replicated association and functional studies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call